Skip to main content
. 2019 Jan 24;53(1):1801919. doi: 10.1183/13993003.01919-2018

TABLE 1.

Summary of measures of health-related quality of life used in pulmonary arterial hypertension (PAH)

Measure [ref.] Domains Items n Recall period
Generic
 SF-36 [9] Physical functioning, role limitations physical, bodily pain, general health, vitality, social functioning, role limitations emotional, mental health 36 Now to past 4 weeks
 EQ-5D [10] Health state description: mobility, self-care, usual activities, pain/discomfort, anxiety/depression; overall health status (visual analogue scale) 51 Today
 NHP [11] Mobility, pain, social isolation emotional reactions, energy level, sleep 38 At the moment
 HADS [12] Anxiety, depression 14 At the moment
PAH specific
 CAMPHOR [13] Overall symptoms (energy, breathlessness, mood), functioning, quality of life 65 Today
 MLHFQ [14] Physical, emotional 21 4 weeks
 LPH [15] Physical, emotional 21 1 week
 CHFQ [16] Dyspnoea, fatigue, emotional function, mastery 20 2 weeks
 emPHasis-10 [17] Unidimensional 10 At the moment
 PAH-SYMPACT [18] Respiratory symptoms, tiredness, cardiovascular symptoms, other symptoms, physical activities, daily activities, social impact, cognition, emotional impact 41 24 h for symptoms; 7 days for imacts

SF-36: Medical Outcomes Study 36-item short form; EQ-5D: EuroQol Group 5-Dimension Self-Report Questionnaire; NHP: Nottingham Health Profile; HADS: Hospital Anxiety and Depression Scale; CAMPHOR: Cambridge Pulmonary Hypertension Outcome Review; MLHFQ: Minnesota Living with Heart Failure Questionnaire; LPH: Living with Pulmonary Hypertension questionnaire; CHFQ: Chronic Heart Failure Questionnaire; emPHasis-10: 10-question survey proposed by the Pulmonary Hypertension Association UK. Information based on and expanded from [6].